Working… Menu
Trial record 4 of 46 for:    SIR-Spheres

SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00503867
Recruitment Status : Terminated (low patient recruitment)
First Posted : July 19, 2007
Last Update Posted : May 7, 2012
Information provided by (Responsible Party):
Sirtex Medical

Brief Summary:
The main purpose of this study is to determine the safety and toxicity of treatment with SIR-Spheres® in patients with unresectable primary liver cancer or hepatocellular carcinoma (HCC). Other purposes of this study include assessment of the effect of treatment on overall survival, the length of time it takes for the disease to worsen, if and how the treatment affects the patient's quality of life, and if and how the cancer responds to the treatment.

Condition or disease Intervention/treatment Phase
Carcinoma, Hepatocellular Hepatoma Device: SIR-Spheres microspheres Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study of Yttrium-90 Microspheres (SIR-Spheres®) Therapy for the Treatment of Unresectable Hepatocellular Carcinoma
Study Start Date : May 2008
Actual Primary Completion Date : December 2010
Actual Study Completion Date : June 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Liver Cancer

Intervention Details:
  • Device: SIR-Spheres microspheres
    SIR-Spheres Yttrium-90 microspheres

Primary Outcome Measures :
  1. safety and toxicity [ Time Frame: for 24 weeks after most recent SIRT treatment, and until death whenever possible ]

Secondary Outcome Measures :
  1. Time to disease progression [ Time Frame: from the date of enrollment to the date of documented progression ]
  2. tumor response [ Time Frame: from the date of enrollment to disease progression or death ]
  3. health related quality of life [ Time Frame: 12 months ]
  4. overall survival [ Time Frame: from the date of enrollment to disease progression or death ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • must have a confirmed diagnosis of HCC.
  • at least 18 years of age.
  • must have a confirmed diagnosis of HCC either by histological confirmation or, in a subject who exhibits a vascular liver mass in the presence of radiographically apparent cirrhosis, an alpha-fetoprotein (AFP) level greater than 500 UI/ml.
  • must present HCC that is not amenable to surgical resection or immediate liver transplantation, or that is not optimally treatable with local ablative techniques such as radio-frequency ablation due to its size, extent or presence of cirrhosis.
  • must present measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension as greater than or equal to 10 mm with spiral CT scan or greater than or equal to 20 mm using conventional techniques (CT, MRI).
  • must present with a whole-liver tumor burden of greater than or equal to 15% and less than or equal to 70%
  • must have an ECOG performance status of 2 or less.
  • must have normal organ and marrow function

Exclusion criteria:

Includes both the listed contraindications to SIR-Spheres® and the exclusion criteria specific to the setting of this investigational study:

  • hepatic artery directed therapy within the previous 6 months.
  • chemotherapy within the previous 4 weeks
  • have not recovered from adverse events due to agents administered previously
  • Prior external hepatic radiation therapy for HCC, more than two prior systemic chemotherapy regimes for HCC or any other concomitant therapy for HCC
  • Currently receiving any other investigational agents for the treatment of their cancer.
  • Any extra-hepatic metastases other than metastatic disease found in the lung, bone and/or abdominal lymph nodes that are not otherwise life limiting.
  • Any other concurrent malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for at least five years.
  • Uncontrolled intercurrent illness or psychiatric illness/social situations that would limit compliance with study requirements.
  • Any of the following contraindications to angiography and selective visceral catheterization:

    • Bleeding diathesis
    • Severe peripheral vascular disease
    • Portal hypertension with hepatofugal flow
  • Female subjects who are pregnant or currently breastfeeding.
  • Refusal or inability to use effective means of contraception in men or women of childbearing potential.
  • Current enrollment in any other investigational drug or device study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00503867

Layout table for location information
United States, Pennsylvania
Thomas Jefferson University - Kimmel Cancer Center
Philadelphia, Pennsylvania, United States, 19107
UPMC Liver Cancer Center
Pittsburgh, Pennsylvania, United States, 15213
United States, Texas
The Liver Institute at Methodist Dallas
Dallas, Texas, United States, 75203
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
Sirtex Medical
Layout table for investigator information
Principal Investigator: Ravi Murthy, MD M.D. Anderson Cancer Center
Principal Investigator: T. Clark Gamblin, MD UPMC Liver Cancer Center

Layout table for additonal information
Responsible Party: Sirtex Medical Identifier: NCT00503867     History of Changes
Other Study ID Numbers: STX 0106
First Posted: July 19, 2007    Key Record Dates
Last Update Posted: May 7, 2012
Last Verified: May 2012
Keywords provided by Sirtex Medical:
unresectable hepatocellular carcinoma
Y-90 Microspheres
liver cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases